Lab Reference Library / C4a (Complement Component 4a) Detox, Mold & CIRS

C4a (Complement Component 4a)

C4a · Complement C4a · C4 Anaphylatoxin

Reference range, optimal functional medicine levels, and why C4a above 2,830 ng/mL is the most sensitive complement marker for biotoxin-driven innate immune activation in CIRS, how HLA-DR genetic susceptibility causes continuous C4a elevation from recirculating biotoxins, and why cholestyramine binder therapy is the primary intervention.

CIRS Primary MarkerSpecialty Testing

NormalBelow 2,830 ng/mL

CIRS SignalAbove 2,830 ng/mL

Unitsng/mL

SpecimenSerum (NJH assay)

← Back to Lab Reference Library

Category: Detox, Mold & CIRS | Also known as: Complement Component 4a, C4 Anaphylatoxin, Complement C4a

1. What This Test Measures

C4a is a low-molecular-weight anaphylatoxin fragment cleaved from complement protein C4 during activation of the classical and lectin complement pathways. The complement system is a network of over 30 serum proteins that constitutes a critical arm of innate immunity, providing rapid non-specific defense against pathogens, clearing immune complexes and cellular debris, and bridging innate to adaptive immune responses. When pattern recognition molecules detect foreign surfaces including bacterial lipopolysaccharide, fungal cell wall components, and biotoxin-modified host proteins, the classical pathway initiates a proteolytic cascade that cleaves C4 into C4a and C4b. C4b opsonizes the target surface; C4a acts as a potent anaphylatoxin that recruits and activates mast cells, basophils, and neutrophils, amplifying local inflammation and increasing vascular permeability.

In normal immune responses, C4a production is transient and tightly regulated. The complement regulatory proteins factor I, factor H, and C4 binding protein rapidly inactivate C4a once its immediate signaling role is complete. The problem in CIRS is that this regulation fails in genetically susceptible individuals: HLA-DR variants that impair normal biotoxin antigen presentation prevent the adaptive immune system from mounting antibody responses that would tag and clear biotoxins, so the innate immune system continues detecting the recirculating biotoxins as foreign material and continues activating complement with every cycle. The result is chronic, sustained C4a elevation that persists long after the patient has left the water-damaged environment.

C4a is measured in the Shoemaker CIRS panel because it is the most sensitive available marker of complement activation specifically driven by biotoxin innate immune stimulation. It rises earlier than C3 (which is consumed and may remain normal from acute-phase production compensation), it is more specific for the classical and lectin pathway activation associated with biotoxin immune recognition than for the alternative pathway, and it has the most extensive validation in the Shoemaker CIRS research database as a marker that tracks both disease severity and treatment response.

2. Reference Range and CIRS Interpretation

C4a Level	Prevalence Context	Interpretation
Below 2,830 ng/mL	Normal population	Normal complement activation; CIRS from this marker unlikely
2,830 to 5,000 ng/mL	Mildly elevated	Early CIRS signal or other complement activation; evaluate full panel and exposure history
5,000 to 10,000 ng/mL	Moderately elevated	CIRS-consistent; correlate with MSH, TGF-beta1, MMP-9, VEGF, and VIP
10,000 to 20,000 ng/mL	Significantly elevated	Strong CIRS signal; comprehensive biotoxin history, HLA-DR testing, and treatment plan required
Above 20,000 ng/mL	Very high	Severe complement activation; aggressive CIRS or concurrent inflammatory disease; urgent evaluation

C4a must be ordered from a laboratory using the assay methodology validated in CIRS research. National Jewish Health and selected specialty reference laboratories provide the appropriate assay. Standard hospital complement panels use different methodology with different reference ranges; results are not interchangeable. Always specify the CIRS research-validated C4a assay when ordering. C4a is stable on serum at room temperature for up to 4 hours; standard handling is adequate.

3. The HLA-DR Genetic Susceptibility Mechanism

The defining feature of CIRS that distinguishes it from a normal acute biotoxin exposure reaction is genetic: approximately 24% of the population carries HLA-DR (human leukocyte antigen class II) variants that impair normal antigen presentation and biotoxin clearance.

In individuals with normal HLA-DR function, biotoxins are processed by antigen-presenting cells, presented to T helper lymphocytes via HLA-DR molecules, and an adaptive immune antibody response is mounted that tags and neutralizes the biotoxins for clearance. The innate immune response, including C4a elevation, resolves once the biotoxins are cleared. In the approximately 24% of the population with susceptible HLA-DR types, biotoxin antigens are not effectively presented, no antibody response is generated, and the biotoxins undergo continuous enterohepatic recirculation without ever being cleared. The innate immune system detects the recirculating biotoxins with every pass through the gut and bloodstream, continuously activating complement and maintaining C4a elevation indefinitely. This is why CIRS patients remain sick long after leaving the water-damaged building and why their cohabitants without the susceptible HLA-DR type may not become ill at all from the same exposure. The difference is not in exposure intensity or psychological vulnerability but in a specific genetic variant in the antigen presentation machinery.

HLA-DR genotyping identifies susceptibility and helps predict which patients will require the full sequential CIRS protocol versus which patients may respond to simpler biotoxin exposure management. Patients with the most susceptible HLA-DR types (particularly those that also impair response to multiple biotoxin categories) require the most aggressive and comprehensive treatment.

4. C4a in the Full CIRS Panel: Pattern Recognition

Classic CIRS Patterns

Full CIRS pattern: C4a markedly elevated, MSH below 35 pg/mL, TGF-beta1 above 2,380 pg/mL, MMP-9 above 332 ng/mL, VEGF below 31 pg/mL, VIP below 23 pg/mL; this combination with a documented water-damaged building exposure history provides high diagnostic confidence for CIRS; HLA-DR testing and VCS testing complete the evaluation
Early CIRS: C4a mildly elevated (2,830 to 5,000 ng/mL) with MSH borderline low (35 to 40 pg/mL) and TGF-beta1 in the high-normal range; other markers may be normal or borderline; represents early-stage CIRS before full downstream regulatory depletion; exposure elimination and binder therapy may produce rapid recovery
Post-exposure CIRS: C4a elevated despite the patient having left the water-damaged building; confirms ongoing biotoxin recirculation through the enterohepatic cycle; patient may have left the building but the biotoxins remain recirculating; binder therapy with confirmed exit from the environment is the intervention
Treatment response monitoring: C4a should fall measurably within 30 days of confirmed exposure elimination and cholestyramine therapy; failure to fall despite apparent protocol compliance suggests ongoing exposure, missed MARCoNS step, or incorrect diagnosis

Atypical Patterns Requiring Evaluation

C4a elevated with normal other CIRS markers: may represent very early CIRS before downstream markers are affected, non-CIRS complement activation from autoimmune disease or infection, or assay variability; repeat testing at 30 days and evaluate for SLE (anti-dsDNA, ANA), active infection, and other complement-activating conditions
C4a normal with other CIRS markers abnormal: may represent Lyme CIRS or tick-borne CIRS where complement activation pathway differs from mold CIRS; consider C3a (alternative pathway marker) as a complement marker in tick-borne CIRS; does not exclude CIRS but changes the etiological investigation
C4a very high (above 20,000 ng/mL) with no biotoxin history: requires evaluation for SLE with active nephritis (immune complex-mediated classical pathway activation), acute infectious complement activation, or another autoimmune condition with significant complement consumption; biotoxin history must be actively sought before attributing to CIRS
C4a not falling despite 30 days of binder therapy: most common cause is ongoing exposure to the original water-damaged environment or a second exposure source not yet identified; second most common is incorrect diagnosis; also consider inadequate binder dosing, binder taken with food rather than between meals, or binder-medication interaction reducing efficacy

5. ERMI Testing and Environmental Investigation

ERMI (Environmental Relative Moldiness Index): a DNA-based dust sampling assay that identifies mold species present in a building and calculates a score based on the ratio of water-damage-indicator molds to common outdoor molds; the gold standard environmental assessment tool for CIRS investigations; a positive ERMI above 2 indicates a water-damaged building that may be driving CIRS; scores above 5 represent significant water damage; available through certified environmental contractors
HERTSMI-2 score: a simplified 5-mold subset of ERMI focused on the most clinically relevant water-damage indicators (Stachybotrys chartarum, Aspergillus penicillioides, Aspergillus versicolor, Wallemia sebi, Chaetomium globosum); a score above 11 indicates a building likely to cause illness in CIRS-susceptible individuals; used for monitoring post-remediation clearance
Visual Contrast Sensitivity (VCS) testing: a neurological screening test measuring the ability to detect contrast gradients; impaired VCS is found in approximately 92% of CIRS patients at baseline and improves with treatment; provides a rapid, inexpensive, reproducible monitoring tool that tracks neurological recovery alongside C4a; available at survivingmold.com
Multiple environments must be assessed: home, workplace, and frequently visited buildings must all be evaluated; C4a failing to fall despite apparent home remediation may indicate ongoing workplace exposure; patients who feel better on vacation but relapse upon returning home have strong ERMI-based evidence for their primary residence as the exposure source

6. How to Reduce C4a: The Binder Protocol

Prescription Binder Therapy

Cholestyramine (CSM) 4g four times daily: the most potent biotoxin binder in the Shoemaker protocol; binds both mycotoxins and other fat-soluble biotoxins in the bile duct before enterohepatic reabsorption; must be taken 30 to 60 minutes before meals and separated from all medications by at least 4 hours due to broad-spectrum binding of drugs; common side effects include constipation and bloating; fiber supplementation and adequate hydration required
Welchol (colesevelam) 625mg three tablets twice daily: similar bile acid sequestrant mechanism to cholestyramine; slightly less potent for biotoxin binding but significantly better tolerated with fewer GI side effects and less medication binding; appropriate for patients who cannot tolerate cholestyramine
Duration and monitoring: 30-day minimum binder course with repeat C4a and TGF-beta1 measurement; if C4a does not fall by at least 20 to 30% at 30 days despite confirmed exposure elimination, evaluate for ongoing exposure source, MARCoNS perpetuation of inflammation, or incorrect diagnosis

Natural Binder Options

Activated charcoal (1 to 2g between meals): broad-spectrum toxin binder; useful as adjunct to prescription binders or as primary binder in patients with mild CIRS; must be separated from medications and supplements
GI Detox or similar clay-charcoal combinations: activated charcoal combined with bentonite clay and other adsorbents; available OTC; weaker binding capacity than prescription CSM but useful as adjunctive support
Chlorella (3 to 5g daily): binds heavy metals and some mycotoxins; evidence for mercury and ochratoxin A binding; useful as part of a comprehensive environmental toxin reduction protocol alongside prescription binders rather than as the primary CIRS binder
Cholestyramine timing notes: the most common protocol error is taking binders with meals or too close to medications; binders taken with food bind dietary fat and nutrients, reducing both efficacy and tolerability; strict between-meal dosing is essential

Environmental and Lifestyle Support

HEPA filtration: high-efficiency particulate air filters in the home (MERV-13 or true HEPA) capture airborne mold spores and mycotoxin-bearing particles; standalone bedroom units and HVAC upgrades reduce ongoing spore load during remediation and recovery
Sauna therapy (infrared or traditional): promotes mycotoxin excretion through sweat alongside the enterohepatic binder approach; adjunctive not primary; start gently in CIRS patients who may have reduced exercise tolerance; 15 to 30 minutes at moderate temperature; ensure hydration and mineral replacement
Low amylose diet: reduces the leptin-MMP-9 amplification loop that sustains complement activation; eliminate high-amylose starches (wheat, corn, rice, potatoes); emphasize non-starchy vegetables, lean protein, olive oil, nuts, and berries
Reduce total biotoxin burden: glyphosate-heavy foods compete with mycotoxin binders; choose organic where possible during binder therapy to reduce competing toxin load and maximize binder efficacy for biotoxin clearance

7. Related Lab Tests

MSHCentral CIRS Regulatory Marker; Low While C4a Is Elevated

→

TGF-beta1Pro-Fibrotic Cytokine Driven by C4a-Initiated Complement Cascade

→

MMP-9Tissue-Degrading Enzyme; Addressed in Protocol After C4a

→

Complement C3Structural Complement Component; C3a is Alternative Pathway Marker

→

Mycotoxin PanelDirect Biotoxin Exposure Confirmation Alongside C4a Immune Response

→

VEGFCapillary Hypoperfusion Companion; Low When C4a Is High

→

8. Clinical Perspective

Clinical Perspective

C4a is the objective anchor of the CIRS diagnosis for me, because it gives the patient something concrete to look at when they have been told for years that there is nothing wrong with them. When C4a comes back at 34,000 ng/mL, that is not a subjective report or a symptom checklist; it is a quantified measurement of how hard their complement system is working, and it is working at a level that would accompany a serious acute bacterial infection in a normal individual. I show patients that number alongside the population reference below 2,830, and the conversation changes completely. They are not imagining their illness. Their innate immune system is in a state of continuous activation that would exhaust anyone, and now we can see why. The second thing C4a gives me is a treatment tracking tool. When I confirm exposure elimination and start cholestyramine therapy and recheck C4a at 30 days, the number tells me whether the intervention is working before the patient's subjective symptoms have fully caught up. A drop from 34,000 to 14,000 at 30 days means the binder is interrupting the recirculation cycle and we advance the protocol. A C4a that has not moved tells me something is still wrong with either the exposure situation or the diagnosis, and we investigate before continuing treatment.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

Why does C4a stay elevated after I leave the moldy building?

C4a remains elevated in HLA-DR-susceptible individuals because biotoxins cannot be cleared through normal antibody-mediated mechanisms. Instead of being neutralized and eliminated, biotoxins undergo continuous enterohepatic recirculation, cycling through the gut, bile duct, and bloodstream with each digestive cycle. The innate immune system detects the recirculating biotoxins as foreign on each pass and activates complement, keeping C4a chronically elevated. Cholestyramine or welchol binder therapy interrupts this cycle by binding biotoxins in the bile before reabsorption.

How quickly should C4a fall with treatment?

With confirmed exposure elimination and cholestyramine 4g four times daily, C4a typically begins to fall within 2 to 4 weeks and shows measurable reduction at the 30-day recheck. The rate of fall depends on biotoxin burden, exposure duration, binder compliance, and whether ongoing exposure sources have been fully identified. Very high baseline values (above 20,000 ng/mL) may require 60 to 90 days to reach below 2,830 ng/mL. C4a that does not fall at 30 days despite apparent protocol compliance signals ongoing exposure or a protocol issue requiring investigation.

Does everyone exposed to mold get elevated C4a?

No. The approximately 76% of the population without susceptible HLA-DR variants can clear biotoxins through normal adaptive immune antibody responses, so their C4a elevation from mold exposure is transient and self-resolving. The approximately 24% with susceptible HLA-DR types cannot generate effective antibody responses to biotoxin antigens and develop the persistent C4a elevation that characterizes CIRS. This is why some family members in a moldy home become severely ill while others seem unaffected: the difference is genetic, not psychological.

What laboratory should I use for C4a testing?

C4a must be ordered from a laboratory using the assay validated in CIRS research. National Jewish Health in Denver, Colorado is the primary reference laboratory recommended in the Shoemaker protocol. Standard hospital complement panels from Quest, LabCorp, or similar commercial laboratories often use different C4a assay methodology with different reference ranges; results from these assays cannot be reliably interpreted using the CIRS reference range of below 2,830 ng/mL. Confirm with your provider that the CIRS-validated assay is being ordered.

Is elevated C4a specific to mold illness?

No. C4a is elevated in any condition producing significant complement activation through the classical or lectin pathways: active SLE with nephritis, acute bacterial infections, Lyme disease CIRS, post-COVID inflammatory syndrome, and other autoimmune conditions with immune complex formation. C4a must be interpreted in the context of the full CIRS panel (MSH, TGF-beta1, MMP-9, VEGF, VIP), biotoxin exposure history, HLA-DR genotyping, and clinical symptoms. Markedly elevated C4a without a plausible biotoxin exposure history requires evaluation for other causes of complement activation before attributing to CIRS.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

C4a above 2,830 ng/mL in the context of water-damaged building exposure and other CIRS markers is the most compelling objective evidence of biotoxin-driven immune activation available.

C4a is the cornerstone of CIRS laboratory evaluation. Schedule a consultation for a comprehensive CIRS panel, exposure history assessment, and structured treatment plan.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.